Intuitive Surgical Gets FDA OK for Latest Robotic System
Provided by
Dow Jones
By Ben Glickman
Intuitive Surgical said Thursday it received approval from U.S. regulators for its latest robotic system for surgery, the da Vinci 5.
The Sunnyvale, Calif.-based company said the U.S. Food and Drug Administration cleared its 510(k) form, allowing Intuitive to bring its product to market.
The company's new multiport robotic system will first be available to a small number of customers in the U.S. who worked with the company during development. Intuitive said it would generate additional data on the system before a wider commercial rollout.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
March 14, 2024 17:02 ET (21:02 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth